Status
Conditions
About
The objectives of the clinical study are to demonstrate the accuracy of our proprietary algorithm method to determine the genetic health of the developing fetuses in a multiple gestation pregnancy from a maternal blood sample. The long term goal of this study will be the development of a method of minimally invasive prenatal diagnosis that has a higher sensitivity and lower false positive rate in the intended population (e.g. multiple gestation pregnancies) than other currently available screening tests.
This will result in fewer unnecessary amniocenteses and Chorionic Villus Sample (CVS) procedures, which are associated with a risk of miscarriage.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Age 18 or older at enrollment
Clinically confirmed multiple gestation pregnancy
Pregnancy at high risk for genetic aneuploidy as defined below:
Confirmed positive aneuploidy by invasive testing
Non invasive prenatal testing "high risk" result
Serum screening risk of greater than 1:100
Ultrasound abnormalities indicative of aneuploidy
Age ≥ 38 years at delivery (if serum screening risk is not less than 1:100)
Gestational age between ≥ 9 weeks, 0 days and ≤26 weeks 0 days by best obstetrical estimate
Able to provide informed consent
Exclusion criteria
99 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal